FDA Approves First Absorbable Coronary Stent

Share this content:
FDA Approves First Absorbable Coronary Stent
FDA Approves First Absorbable Coronary Stent

TUESDAY, July 5, 2016 (HealthDay News) -- The first coronary stent to be gradually absorbed by the body has been approved by the U.S. Food and Drug Administration.

The Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) is absorbed within about three years, the agency said Tuesday in a news release. The stent also releases the drug everolimus to limit the growth of scar tissue.

The newly approved stent is made from a biodegradable polymer called poly(L-lactide), which is similar to materials used in other types of absorbable medical devices, the agency noted. In this case, the device's absorption rids the affected artery of foreign material once it's no longer necessary, the FDA said. Once the product disintegrates, four platinum markers are left to indicate where the stent had been implanted.

The product was evaluated in a clinical study involving 2,008 people. The major cardiac adverse event rate in the Absorb GT1 BVS group was 7.8 percent, which was deemed clinically comparable to the rate observed in the control group (6.1 percent). The rate of blood clots forming within the devices was 1.54 percent for the Absorb GT1 BVS and 0.74 percent for the control, according to the FDA.

The new stent is produced by Santa Clara, California-based Abbott Vascular.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Critics Demand Stop to 'Guinea Pig' Sepsis Clinical Trial

Critics Demand Stop to 'Guinea Pig' Sepsis Clinical ...

Clovers trial seeks to determine which IV fluids, vasopressors combo works best to curb sepsis

Education Can Up Emotional Intelligence in Residents

Education Can Up Emotional Intelligence in Residents

Increase in total EI median scores, stress management composite score after intervention

Cancer-Related Gene Variations Frequently Reclassified

Cancer-Related Gene Variations Frequently Reclassified

24.9 percent of variants of uncertain significance were reclassified at a single commercial laboratory

is free, fast, and customized just for you!




Already a member?

Sign In Now »